Charnwood Discovery and Intelligent Omics Announce Strategic Collaboration

Charnwood Discovery a leading drug discovery research partner has announced a strategic collaboration with Intelligent OMICS Ltd (Intellomx) who specialise in applying artificial intelligence (AI) and Machine Learning (ML) to accelerate drug discovery.
The collaboration will enable Charnwood Discovery to enhance its already extensive drug discovery services through Intellomx's AI platform which enables the identification of previously unattainable targets.
Dr Francesca Sadler, Charnwood Discovery's Chief Commercial Officer commented:
"This exciting collaboration with Intellomx will help us to further enhance our global clients' experience and success of drug discovery. Their innovative use of AI and ML to gain a deeper understanding of diseases perfectly complements our own services from standalone through to fully integrated drug discovery. "

Dr Robert Grundy, CEO of Intelligent OMICS adds:
"I'm certain that this collaboration with Charnwood Discovery will enable us to showcase our revolutionary technology to a wider audience and help them accelerate their discovery programs.
By delving deep into transcriptomic, genomic and proteomic data sets, novel biological targets are uncovered and existing pathways validated, paving the way for groundbreaking treatments."

Shona Farmer
Marketing Manager
Charnwood Discovery
Charnwood Campus
9 Summerpool Road
Loughborough
UK
LE11 5RD

Charnwood Discovery is a leading provider of drug discovery services, from standalone customized solutions through to fully integrated programs that enhance the experience and success of complex drug discovery.

Founded in 1998 we have grown and expanded to offer multiple services across chemistry, bioscience and ADME / DMPK and are an established partner of choice for many biotech and pharmaceutical companies.

Our client centric, flexible approach, combined with a commitment to innovation and excellence sees many clients return to us year on year to support their research programs.

Working in collaboration we add value across the drug discovery pipeline, from target validation through to pre-clinical candidates.

Whether you need a standalone or fully integrated solution our multidisciplinary teams provide innovation and excellence at every stage.

This release was published on openPR.